BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Bambusa Therapeutics Initiates First Clinical Trial for BBT001 a Bispecific Antibody Targeting Atopic Dermatitis

Preclinical data with BBT001 demonstrate its best-in-disease potential for improved efficacy and dosing convenience compared to approved biologics in atopi...

March 03, 2025 | News

China Fapon Biopharma secures US FDA IND approval for FP008 a first-in-class immunocytokine for resistant solid tumors

Fapon Biopharma, a biotech innovator in developing therapeutic antibodies and fusion proteins, is pleased to announce that the U.S. Food and Drug Administr...

March 03, 2025 | News

Alphamab Oncology and CSPC Dose First Patient in Phase III Trial of JSKN003 for HER2-Positive Breast Cancer

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has...

February 28, 2025 | News

Akeso Enrolls First Patient in Phase I Trial for HER3-Targeting ADC AK138D1 in Australia

Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in...

February 28, 2025 | News

Kangpu Biopharma Secures China IND Approval for KPG-818 in Relapsed/Refractory Multiple Myeloma

Kangpu Biopharmaceuticals, Ltd. ("Kangpu") announced that the Company has received IND approval from the CDE (Center for Drug Evaluation) of China National...

February 26, 2025 | News

HBM Alpha Therapeutics Secures $395M Licensing Deal to Advance CRH-Targeting Therapy

HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced a strategic collaborati...

February 26, 2025 | News

Telix’s Kidney Cancer Imaging Agent Gains FDA Priority Review, Eyes 2025 Launch

Telix Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for TLX25...

February 26, 2025 | News

Innovent’s Ipilimumab NDA Accepted by China’s NMPA with Priority Review for MSI-H/dMMR Colon Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

February 25, 2025 | News

LabConnect and ACL Specialised Trials Partner to Strengthen Clinical Trial Support in Australia and APAC

LabConnect and Australian Clinical Labs' (ACL) Specialised Trials have forged a strategic partnership to expand support of clinical trials in Aus...

February 25, 2025 | News

Akeso Begins Phase III Trial of Ivonescimab for First-Line Treatment of Advanced Triple-Negative Breast Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient in its multicenter, ran...

February 24, 2025 | News

Chime Biologics and Mabgeek Advance MG-K10 to U.S. Phase III Trials for Atopic Dermatitis and Asthma

Chime Biologics, a leading global CDMO that enables its partners' success in biologics, announced its continued collaboration with Mabgeek ...

February 24, 2025 | News

Akeso Doses First Patient in Phase III Trial of Ivonescimab for First-Line Treatment of Triple-Negative Breast Cancer

Akeso, Inc. announced the company has successfully enrolled the first patient in its multicenter, randomized, double-blind Phase III clinical trial of...

February 21, 2025 | News

Ascletis’ ASC30 Oral Tablet Shows Promising Weight Loss in U.S. Phase Ib Obesity Trial

- ASC30 oral once-daily tablet demonstrated a 6.3% mean body weight reduction from baseline after 28-day treatment in multiple ascendi...

February 20, 2025 | News

Australia’s Clarity Pharmaceuticals Secures FDA Fast Track for 67Cu-SAR-bisPSMA in Prostate Cancer

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation pr...

February 20, 2025 | News

Stay Connected